Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Cormedix org - The Real Truth

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

CorMedix (NASDAQ:CRMD) CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath uti

CorMedix Q1 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments. Chairman and Chi

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why CorMedix Could be the Biopharma Name to Watch Early in 2026

CorMedix is a promising biopharma firm in the catheter lock solution space. Continued success for its top products could fuel significant growth into 2026.

MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details

CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

inkl

Read news from The Economist, FT, and more,
with one subscription

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Cormedix: Q1 Earnings Insights

Cormedix: Q1 Earnings Insights

Cormedix (NASDAQ:CRMD) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cormedix beat estimated earnings by 18.18%, reporting an EPS of $-0.18 versus an estimate of $-0.22.

Cormedix's Return On Capital Employed Insights

Cormedix's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, Cormedix's (NASDAQ:CRMD) reported sales totaled $56.40 thousand. Despite a 9.08% increase in earnings, the company posted a loss of $7.79 million.

CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Inc (NASDAQ: CRMD) has resubmi

1

Organisations

Medicare Advantage

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

infectious disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play